INmune Bio, Inc. $INMB Shares Sold by MAI Capital Management

MAI Capital Management decreased its position in INmune Bio, Inc. (NASDAQ:INMB) by 54.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,238 shares of the company’s stock after selling 58,559 shares during the quarter. MAI Capital Management owned 0.18% of INmune Bio worth $111,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in INMB. Geode Capital Management LLC lifted its stake in INmune Bio by 6.9% during the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after purchasing an additional 25,069 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of INmune Bio by 1,042.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after buying an additional 66,700 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of INmune Bio by 9.0% in the 1st quarter. Bank of New York Mellon Corp now owns 54,923 shares of the company’s stock valued at $429,000 after buying an additional 4,521 shares during the period. Focus Partners Advisor Solutions LLC boosted its holdings in shares of INmune Bio by 321.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock valued at $113,000 after buying an additional 37,224 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of INmune Bio by 19.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock valued at $323,000 after buying an additional 6,654 shares during the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Sunday, November 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $18.00.

INmune Bio Trading Up 4.2%

NASDAQ INMB opened at $1.72 on Friday. The company has a 50-day moving average price of $1.79 and a two-hundred day moving average price of $3.32. INmune Bio, Inc. has a 52 week low of $1.38 and a 52 week high of $11.64. The stock has a market cap of $45.69 million, a price-to-earnings ratio of -0.81 and a beta of 0.95.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.07. As a group, equities research analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.